N-[3-(2-dimethylaminoethyl).2-methyl-1H-indol-5-yl]-4-fluorobenzamide: A potent, selective, and orally active 5-HT1F receptor agonist potentially useful for migraine therapy

Journal of Medicinal Chemistry

Volumn 44, Issue 24, 2001, Pages 4031-4034

  Xu, Y C ^a   Johnson, K W ^a   Phebus, L A ^a   Cohen, M ^a   Nelson, D L ^a   Schenck, K ^a   Walker, C D ^a   Fritz, J E ^a   Kaldor, S W ^a   LeTourneau, M E ^a   Murff, R E ^a   Zgombick, J M ^b   Calligaro, D O ^a   Audia, J E ^a   Schaus, J M ^a  

^a ELI LILLY AND COMPANY   (United States)

^b H LUNDBECK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 (4 FLUOROBENZAMIDO) 3 (1 METHYL 4 PIPERIDINYL) 1H INDOLE FUMARATE; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIMIGRAINE AGENT; FLUNITRAZEPAM; MEPYRAMINE; MUSCIMOL; N [3 (2 DIMETHYLAMINOETHYL) 2 METHYL 1H INDOL 5 YL] 4 FLUOROBENZAMIDE; NARATRIPTAN; PRAZOSIN; RACLOPRIDE; RAUWOLSCINE; RIZATRIPTAN; SEROTONIN; SUMATRIPTAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; MIGRAINE; NONHUMAN; RABBIT; RAT; SAPHENOUS VEIN; STRUCTURE ACTIVITY RELATION;

ANIMALS; BENZAMIDES; CELL LINE; DURA MATER; GUINEA PIGS; HUMANS; INDOLES; INFLAMMATION; MIGRAINE DISORDERS; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; RABBITS; RATS; RECEPTORS, NEUROTRANSMITTER; RECEPTORS, SEROTONIN; SAPHENOUS VEIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035935671     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0155190     Document Type: Article

References (43)

1. The pharmacology and therapeutic potential of serotonin receptor agonists and antagonists
2. Serotonin receptors: Clinical implications
3. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine
4. 5-Hydroxytryptamine receptor subtypes: Molecular, biochemical and physiological characterization
5. Molecular cloning of a human gene (S31) encoding a novel serotonin receptor mediating inhibition of adenylyl cyclase
6. Sumatriptan in the treatment of Migraine
7. Sumatriptan: A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache
8. Clinical and experimental effects of sumatriptan in humans
9. 1D binding sites
10. 1D receptors: Pharmacology and therapeutic potential
11. 1F receptor agonists inhibit neurogenic dural inflammation in guinea pigs
12. 1Dβ receptors
13. Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraine
14. 1F receptor
15. 1F receptor agonist
16. 1F receptor agonist
17. Stereoselective syntheses of isoquinuclidones
18. Studies on the Fischer indole synthesis
19. The Fischer indolization of 4-acetonyl-2,6-piperidinediones
20. Synthesis of cis- and trans-1-substituted 1,2,3,4,4a,5,11,11a-octahydro-6H-pyrido[3,2-b]carbazoles, 4-substituted 1,2,3,4,4a,5,6,11c-octahydro-7H-pyrido[2,3-c]carbazoles, cis-4-methyl-1,2,3,4,4a,5,6,12b-octahydro-7h-pyrido[2,3-c] acridine and cis-1-methyl-1,2,3,4,4a,5,12,12a -octahydro-6H-pyrido[3,2-b]acridine - A new class of potential antiparkinsonian agents
21. 1 receptor subtype coupled to the inhibition of adenylate cyclase
22. 1F receptor to multiple signal transduction pathways
23. Expression and pharmacological characterization of a canine 5-hydroxytryptamine 1D receptor subtype
24. 1Dβ
25. Pharmacologic characterization of the human 5-hydroxytryptamine 2B receptor: Evidence for species differences
26. 7 receptor in rat brain
27. Binding characteristics of 3H-prazosin to rat brain α-adrenergic receptors
28. Pharmacological evidence for alpha-2 adrenoceptor heterogeneity: Differential binding properties of [3H]rauwolscine and [3H]idazoxan in rat brain
29. Beta adrenergic receptor binding in membrane preparations from mammalian brain
30. Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum
31. Raclopride, a new selective ligand for the dopamine-D2 receptors
32. Specific benzodiazepine receptors in rat brain characterized by high-affinity [3H]-diazepam binding
33. Characterization of the binding of tritiated [3H]muscimol, a potent γ-aminobutyric acid agonist, to rat brain synaptosomal membranes using a filtration assay
34. Histamine H1 receptors identified in mammalian brain membranes with [3H]-mepyramine
35. Muscarinic cholinergic binding in rat brain
36. Neurotransmitters and the fifth cranial nerve: Is there a relation to the headache phase of migraine?
37. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain
38. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
39. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: Results of two randomized, double-blind, placebo-controlled clinical trials
40. The non-peptide NK-1 receptor antagonist LY303870 inhibits neurogenic dural inflammation in guinea pigs
41. A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation
42. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein